Related Experiment Video
Updated: May 5, 2026
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
9.5K
Presymptomatic targeted circuit manipulation for ameliorating Huntington's disease pathogenesis
Ebenezer C Ikefuama1, Ashley N Slaviero2, Alexander D Silvagnoli1
1Program in Neuroscience, Central Michigan University, Mount Pleasant, MI 48859, USA.
Iscience
|March 17, 2025
Summary
Targeting early Huntington's disease (HD) by adjusting brain circuit activity before symptom onset can slow disease progression. Modulating specific neuron types in the motor cortex improved motor function in a mouse model, offering a potential therapeutic strategy.
Area of Science:
- Neuroscience
- Neurodegenerative Disorders
- Molecular Biology
Background:
- Huntington's disease (HD) involves excitatory/inhibitory (E/I) imbalance in brain circuits before motor and cognitive symptoms appear.
- This pre-symptomatic window offers a critical opportunity for therapeutic intervention to restore E/I balance and slow disease progression.
Purpose of the Study:
- To investigate the impact of cell-type specific modulation of M1 motor cortex activity on disease progression in a pre-symptomatic HD mouse model.
- To determine if dampening pyramidal neuron excitation or increasing interneuron activity can alleviate early HD-related deficits.
Main Methods:
- Utilized the R6/2 mouse model of Huntington's disease.
- Administered daily, cell-type specific manipulations of pyramidal neurons (Emx1) and parvalbumin interneurons in the M1 motor cortex for three weeks during the pre-symptomatic phase.
- Assessed effects on motor coordination and disease progression.
Main Results:
- Dampening Emx1 pyramidal neuron excitation significantly alleviated HD-related motor coordination dysfunction.
- Increasing parvalbumin interneuron activity also ameliorated motor deficits in the pre-symptomatic HD mouse model.
- These findings demonstrate that normalizing cortical output via cell-type specific modulation is effective in an HD model.
Conclusions:
- Cell-type specific modulation of cortical microcircuits represents a promising therapeutic strategy for Huntington's disease.
- Targeting E/I balance in the pre-symptomatic phase can prevent or slow the progression of motor deficits in HD.
- This approach may also be applicable to other neurodegenerative disorders characterized by circuit dysfunction.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:21Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110